A5022249692- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Global Cancer Incidence and Screening
- Acute Lymphoblastic Leukemia research
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Lymphoma Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Economic and Financial Impacts of Cancer
- Nausea and vomiting management
- Peptidase Inhibition and Analysis
- Health Systems, Economic Evaluations, Quality of Life
- Advances in Oncology and Radiotherapy
- BRCA gene mutations in cancer
- Multiple and Secondary Primary Cancers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Acute Myeloid Leukemia Research
- Neutropenia and Cancer Infections
- Childhood Cancer Survivors' Quality of Life
- Eosinophilic Disorders and Syndromes
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chemotherapy-related skin toxicity
- Multiple Myeloma Research and Treatments
Rashid Latif Medical College
2014-2025
Ungku Omar Polytechnic
2024
University of Miami
2024
University of Tikrit
2023
Latifa Hospital
2023
American Society of Clinical Oncology
2022
Chittaranjan National Cancer Institute
2022
Instituto Nacional de Cancerología
2022
Komfo Anokye Teaching Hospital
2022
Allama Iqbal Medical College
2004-2021
Purpose Lapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human 2 (HER-2/ErbB2), is effective against HER-2–positive locally advanced or metastatic breast cancer (MBC). This phase III trial evaluated the efficacy lapatinib in HER-2–negative HER-2–uncharacterized MBC. Patients Methods Women with MBC were randomly assigned to first-line therapy paclitaxel 175 mg/m every 3 weeks plus 1,500 mg/d placebo. A preplanned retrospective evaluation HER-2...
This study (EGF20009) assessed the efficacy and tolerability of two lapatinib administration schedules as first-line monotherapy in women with ErbB2-amplified locally advanced or metastatic breast cancer.Patients ErbB2-amplified, cancer previously untreated setting were randomly assigned to one dose cohorts received either 1,500 mg once daily 500 twice daily. Clinical response was at weeks 8 12 every thereafter.A total 138 patients treated for a median 17.6 weeks. The overall rate (complete...
•Final safety and efficacy results from PERUSE with ∼6 years' median follow-up are consistent CLEOPATRA results.•Results provide reassurance that paclitaxel is a valid alternative to docetaxel first-line pertuzumab trastuzumab.•In exploratory analyses, presence of both visceral disease prior trastuzumab identified subgroup worse PFS. BackgroundThe phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination pertuzumab, as standard therapy for...
A consensus meeting of national experts from all major hepatobiliary centres in the country was held on May 26, 2023, at Pakistan Kidney and Liver Institute & Research Centre (PKLI RC) after initial consultations with experts. The Society for Study Diseases (PSSLD) PKLI RC jointly organised this meeting. This effort based a comprehensive literature review to establish practice guidelines hilar cholangiocarcinoma (hCCA). that hCCA is complex disease requires multidisciplinary team approach...
The purpose of this phase III trial was to evaluate the efficacy and safety regimens containing casopitant, a novel neurokinin-1 receptor antagonist, for prevention chemotherapy-induced nausea vomiting during first cycle in patients receiving moderately emetogenic chemotherapy (MEC).Predominantly female (98%) diagnosed with breast cancer (96%) who were chemotherapy-naïve scheduled receive an anthracycline cyclophosphamide (AC) -based regimen enrolled onto multinational, randomized,...
To provide expert guidance to clinicians and policymakers in three resource-constrained settings on diagnosis staging of adult women with ovarian masses treatment patients epithelial (including fallopian tube primary peritoneal) cancer.
Treating breast cancer under the constraints of significantly limited health care resources poses unique challenges that are not well addressed by existing guidelines. We present evidence-based guidelines for systematically prioritizing therapies across entire spectrum resource levels. After consideration factors affecting value a given therapy (contribution to overall survival, disease-free quality life, and cost), we assigned each one four incremental levels--basic, limited, enhanced, or...
We evaluated the efficacy and toxicity of gemcitabine with or without cisplatin in 11 chemonaive patients histologically confirmed advanced gallbladder cancer. All were symptomatic had stage IV disease. Eight received 1 g/m2 on days 8 along 70 mg/m2 day 1. Three alone. Treatment cycles repeated every 21 days. One patient (9%) complete remission disease 6 (55%) achieved a partial response to chemotherapy an overall rate 64%. Median time progression was 28 weeks median survival 42 weeks....
Abstract A founder allele in the CHEK2 gene (1100delC) has been associated with an elevated risk of breast cancer. This is responsible for majority CHEK2-associated cancers women from northern European countries; however, within Europe, it seems to be rare countries that are close Mediterranean. The frequency 1100delC not measured non-White populations. We 3,882 cancer patients and 8,609 controls various countries. was seen among Asian (from Pakistan or Philippines) present 1 155 cases...
Introduction Pediatric low-grade glioma (LGG) is a World Health Organization (WHO) Global Initiative for Childhood Cancer (GICC) index tumor constituting up to third of pediatric central nervous system (CNS) tumors. The baseline characteristics, survival, and management resources LGG in Africa are unknown. We aimed evaluate the neuro-oncology multidisciplinary team resources, epidemiology, survival outcomes document information prior GICC implementation. Methods study consisted two parts:...
Abstract Background: Ovarian cancer is the sixth leading cause of deaths among women in United States. South Asians USA, including Asian Indians and Pakistani Americans (AIPA), are a rapidly growing yet under-researched group. This study aims to analyze clinical features, survival rates, treatment, outcomes ovarian AIPA Methods: Adult diagnosed with between 2000 2023 within Surveillance, Epidemiology, End Results (SEER) registry were identified utilizing ICD codes. The analysis focused on...
A multicenter prospective nonrandomized trial was conducted to evaluate the efficacy of self-administered oral ofloxacin in treatment cancer patients with fever and neutropenia. Patients receiving chemotherapy who either resided far away were unable reach oncology ward within 12 hours onset or afford expensive inpatient care eligible for inclusion study. Requirements enrollment included an absolute neutrophil count ⩽0.5 × 109/L, a temperature >38°C, ability take medications. The instructed...
The management of locally advanced breast cancer (LABC) is guided by scientific advances but limited local resources and expertise. LABC remains very common in low-resource countries. Systemic Therapy Focus Group met as part the Breast Health Global Initiative (BHGI) Summit Budapest, Hungary, October 2007 to discuss implementation primary systemic therapy (PST) for LABC. PST standard treatment large operable enhanced-resource settings and, all resource settings, should be inoperable Standard...
There is paucity of data from developing countries on the efficacy and safety imatinib mesylate in chronic myeloid leukemia (CML). The primary objective this study was to document complete partial cytogenetic responses all phases CML. Secondary objectives included evaluations hematologic response, safety, time progression, survival.Two hundred seventy-five patients CML who received treatment with January 2001 December 2005 were study. All had bone marrow or BCR-ABL positive peripheral blood...
Treatment of chronic myeloid leukemia (CML) is challenging in patients who want to conceive. We followed 809 with CML treated imatinib mesylate (IM). observed outcomes 90 pregnancies from 61 (21 females, 40 males) conceived while on IM. Information was obtained duration exposure IM, pregnancy termination and congenital abnormalities. Hematologic cytogenetic responses were also recorded. Twenty-eight occurred among 62 reported male patients. Among female patients, 19 (67.9%) uneventful six...